Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 32(7): 2849-54, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22753747

ABSTRACT

BACKGROUND: Cell viability assays are important tools in oncological research. The purpose of this study was to evaluate the effect of docetaxel, doxorubicin and cyclophosphamide on the metabolic activity of MCF-7 breast cancer cell line. MATERIALS AND METHODS: Antiproliferative effect of cytostatics on MCF-7 cells was measured using the standard colorimetric test. The MCF-7 cell line was exposed to cytostatics for 24 hours. The metabolic activity was evaluated over the 24 hours. RESULTS: According to the statistical analysis, the change in the growth rate was significant (p<0.05) for the 120 nM docetaxel and above the 200 nM doxorubicin treatment in comparison with sensitive MCF-7 cells. When considering drugs in combination (60 nM docetaxel with 200 nM doxorubicin and 60 nM docetaxel with 500 nM doxorubicin) after the addition of 600 nM cyclophosphamide, we found a statistically significant decrease of metabolic activity of the MCF-7 cell line (p<0.05). CONCLUSION: Cyclophosphamide at 600 nM seems to enhance the influence of docetaxel when combined with doxorubicin.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Survival/drug effects , Colorimetry , Cyclophosphamide/administration & dosage , Docetaxel , Doxorubicin/administration & dosage , Drug Synergism , Female , Humans , Taxoids/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...